Adelle Diagnostics
MedTech startup focused on biomarker discovery and development of molecular diagnostics for neurodegenerative diseases, with a particular emphasis on Normal Pressure Hydrocephalus (NPH). Combines multi-omics molecular profiling (CSF and blood), high-throughput data generation, and machine learning/statistical modeling to identify and validate diagnostic biomarkers and develop minimally invasive tests to support clinical decision-making and predict benefit from shunt surgery.
Industries
Nr. of Employees
small (1-50)
Adelle Diagnostics
Providence, Rhode Island, United States, North America
Products
Molecular diagnostic test for NPH and prediction of shunt benefit
A laboratory-developed diagnostic assay based on molecular biomarkers to diagnose Normal Pressure Hydrocephalus and predict patient benefit from shunt surgery.
Molecular diagnostic test for NPH and prediction of shunt benefit
A laboratory-developed diagnostic assay based on molecular biomarkers to diagnose Normal Pressure Hydrocephalus and predict patient benefit from shunt surgery.
Services
Biomarker discovery and validation using multi-omics and AI
Identification and validation of diagnostic biomarkers through integrated multi-omics profiling and machine learning analysis to support diagnostic test development.
Biomarker discovery and validation using multi-omics and AI
Identification and validation of diagnostic biomarkers through integrated multi-omics profiling and machine learning analysis to support diagnostic test development.
Expertise Areas
- Biomarker discovery and validation
- Multi-omics data integration
- Neurodegenerative disease diagnostics (focus on NPH)
- Machine learning for clinical diagnostics
Key Technologies
- Next-generation RNA sequencing (RNA-seq)
- High-resolution mass spectrometry
- Immunoassays (ELISA)
- Machine learning and statistical modeling